Buchumschlag

Use of Droplet Digital PCR for Consistent Detection of TMPRSS2:ERG Gene Fusion Transcripts Initiated In Vitro

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Megan H. Check, Sarah E. Ernst, Karen S. Sfanos
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2025
Schlagworte:	The Prostate
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Role of Cell‐Cycle Proliferation Test, Triple Hit Phenotype, and TMPRSS2‐ERG Expression to Evaluate the Risk of Progression in Prostate Cancer Patients Under Active Surveillance
von: Marco Oderda, et al.
Veröffentlicht: (2025)

ERG and PTEN Role on Active Surveillance for Low‐Risk Prostate Cancer in the Multiparametric MRI Era
von: Marco Aurelio Watanabe Yorioka, et al.
Veröffentlicht: (2024)

Muscadine Grape Skin Extract in Biochemically Recurrent Prostate Cancer: A Randomized, Placebo‐Controlled, Biomarker‐Enriched Trial in Patients With the SOD2 Ala/Ala Variant
von: A. Mandl, et al.
Veröffentlicht: (2025)

Impact of Genomic Mutations on the Transcriptional Pathways and Tumor Microenvironment Landscape of Localized Early Prostate Cancer
von: William Lautert‐Dutra, et al.
Veröffentlicht: (2026)

pSTAT3 Expression is Increased in Advanced Prostate Cancer in Post‐Initiation of Androgen Deprivation Therapy
von: Piotr Bialas, et al.
Veröffentlicht: (2024)

Confirmation of BIK and SAMHD1 as Prostate Cancer Susceptibility Genes
von: Christian P. Pavlovich, et al.
Veröffentlicht: (2025)

Combining Prostate‐Specific Antigen Density With PI‐RADS to Improve the Detection of Clinically Significant Prostate Cancer at MRI/TRUS Fusion‐Targeted Re‐Biopsy
von: Yuto Ono, et al.
Veröffentlicht: (2025)

A Gene Expression Tumor Signature Optimizing Partial Area‐Under‐the‐Curve (pAUC) to Improve Specificity for Indolent Prostate Cancer
von: Travis A. Gerke, et al.
Veröffentlicht: (2026)

Developments in Ultrasound‐Based Imaging for Prostate Cancer Detection
von: Reid Vassallo, et al.
Veröffentlicht: (2025)

Reply – Letter to the Editor: Bimodal Imaging at MRI Fusion Prostate Biopsy Will Gain Further Importance in the Future
von: Fabian Falkenbach, et al.
Veröffentlicht: (2025)

Automatic MRI‐TRUS Fusion Technique for Transperineal Biopsy Guidance: From Preoperative Planning to Intraoperative Navigation
von: Lu Tang, et al.
Veröffentlicht: (2024)

Consistent predictive ability of prostate‐specific antigen density prediction model for clinically significant prostate cancer across age strata
von: Kamil Malshy, et al.
Veröffentlicht: (2024)

Corticosteroid Use and Risk of Adverse Events in Metastatic Hormone‐Sensitive Prostate Cancer
von: Umang Swami, et al.
Veröffentlicht: (2026)

Racial Disparities in the Use of MRI and PET Scan Among Medicare Beneficiaries With Prostate Cancer
von: Hanna Zurl, et al.
Veröffentlicht: (2025)

Is Saturation Biopsy Still a Viable Alternative to Fusion Biopsy in the Era of Multiparametric MRI? A Comparative Analysis in Patients With Prior Negative Biopsy
von: Arda Taşkın Taşkıran, et al.
Veröffentlicht: (2026)

In Vitro Effects of Cabazitaxel and Menadione on Cell Growth, Metabolism, and Transcriptomic Profile of Human Prostate Cancer Cell Lines
von: Ana Laura Gómez-Rosas, et al.
Veröffentlicht: (2026)

Downregulation of NONO Suppresses Proliferation, Migration, and Invasion in Metastatic Prostate Cancer
von: Anna‐Lena Lemster, et al.
Veröffentlicht: (2025)

The Role of Secondary Lesion Biopsy in Detecting Clinically Significant Prostate Cancer
von: Trevor C. Hunt, et al.
Veröffentlicht: (2025)

Clinical validation of circulating GDF15/MIC‐1 as a marker of response to docetaxel and survival in men with metastatic castration‐resistant prostate cancer
von: Kate L. Mahon, et al.
Veröffentlicht: (2024)

Bimodal imaging: Detection rate of clinically significant prostate cancer is higher in MRI lesions visible to transrectal ultrasound
von: Fabian Falkenbach, et al.
Veröffentlicht: (2024)

Utility of the PROSTest, a Novel Blood‐Based Molecular Assay, Versus PSA for Prostate Cancer Stratification and Detection of Disease
von: Mark Kidd, et al.
Veröffentlicht: (2025)

Influence of 5‐Alpha Reductase Inhibitors on PI‐RADS Scores and Prostate Cancer Detection: A Systematic Review and Meta‐Analysis
von: Lian Qiong, et al.
Veröffentlicht: (2025)

Socioeconomic and Demographic Factors in Genetic Testing Utilization Among Advanced Prostate Cancer Patients
von: Alexandra T. Skowron, et al.
Veröffentlicht: (2026)

Cancer cells employ lipid droplets to survive toxic stress
von: Laurie G. Kostecka, et al.
Veröffentlicht: (2024)

Co‐targeting SKP2 and KDM5B inhibits prostate cancer progression by abrogating AKT signaling with induction of senescence and apoptosis
von: LaKendria K. Brown, et al.
Veröffentlicht: (2024)

Comparative Evaluation of Detection Rates for Clinically Significant Prostate Cancer Using MRI‐Targeted Biopsy Alone Versus in Combination With Systematic Biopsies: Development of a Risk‐Stratification Scoring System
von: Toshifumi Takahashi, et al.
Veröffentlicht: (2024)

Human Epidermal Growth Factor Receptor 2 Expression in Prostatic Carcinomas: A Systematic Review and Meta‐Analysis of a Potential Therapeutic Target
von: Jacky T. F. Luk, et al.
Veröffentlicht: (2026)

Beyond Baseline: Serial PSA Measurements and Risk Stratification for Prostate Cancer
von: Anwar E. Ahmed, et al.
Veröffentlicht: (2025)

Distribution of neurovascular structures within the prostate gland and their relationship to complications after radical prostatectomy
von: Ghazi Alanazi, et al.
Veröffentlicht: (2024)

RETRACTION: Glyoxalase 2 Is Involved in Human Prostate Cancer Progression as Part of a Mechanism Driven By PTEN/PI3K/AKT/mTOR Signaling With Involvement of PKM2 and ERα
Veröffentlicht: (2024)

Erratum to “Inhibition of Signaling Downstream of Beta‐2 Adrenoceptor by Propranolol in Prostate Cancer Cells”
Veröffentlicht: (2025)

Deep PSA response and extended time‐to‐nadir as robust predictors of survival in Asian patients with de novo metastatic hormone‐sensitive prostate cancer receiving upfront intensified treatment
von: Chris H.‐M. Wong, et al.
Veröffentlicht: (2024)

Effects of Concurrent Administration of Spironolactone in Veterans with Metastatic Prostate Cancer Receiving Abiraterone: A Real‐World Retrospective Study
von: Erum Z. Whyne, et al.
Veröffentlicht: (2024)

Modern predictors and management of incidental prostate cancer at holmium enucleation of prostate
von: Eric V. Li, et al.
Veröffentlicht: (2024)

Incidental Brain Metastases From Prostate Cancer Diagnosed With PSMA PET/CT and MRI: A Case Series and Literature Review
von: Mark Willy L. Mondia, et al.
Veröffentlicht: (2025)

Individualized Precision Prostate Biopsy Strategy for Patients With PI‐RADS Score 2: A Retrospective Multicenter Study
von: Zhiyao Xu, et al.
Veröffentlicht: (2025)

MEIS2 Modulates Oxidative Phosphorylation and ROS Generation to Affect CD8 + T Cell Antitumor Immunity in Prostate Cancer
von: Dengjun Han, et al.
Veröffentlicht: (2025)

An orthotopic prostate cancer model for new treatment development using syngeneic or patient‐derived tumors
von: Naz Chaudary, et al.
Veröffentlicht: (2024)

Efficacy, tolerability, and safety of teverelix DP in patients with advanced prostate cancer: A multicenter, open‐label, phase 2 trial
von: Albertas Ulys, et al.
Veröffentlicht: (2024)

Link between circadian rhythm and benign prostatic hyperplasia (BPH)/lower urinary tract symptoms (LUTS)
von: Dana Cavanaugh, et al.
Veröffentlicht: (2024)